Juvenile Huntington's Disease FDA Patient Listening Session Summarykatie8288Apr 4, 20230 min readJoHD FDA PLS Review.pdfDownload PDF • 509KB
Skyhawk Therapeutics Announces First U.S. Patients Dosed in Pivotal FALCON-HD Study Evaluating SKY-0515 in Huntington's Disease
uniQure Announces FDA Acceptance and Priority Review of the Biologics License Application for ifezuntirgene inilparvovec for the Treatment of Huntington’s Disease
Comments